患有血液性恶性瘤的重症患者的长期生存和功能结果:加拿大多中心前性研究
Laveena Munshi1,2, Guillaume Dumas3, Bram Rochwerg4,5
1Interdepartmental Division of Critical Care Medicine, Department of Medicine, Sinai Health System, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, ON, M5G 1X5, Canada. Laveena.munshi@sinaihealth.ca.
Intensive care medicine
|March 11, 2024
概括
患有血液性恶性瘤 (HM) 的重症患者的长期存活率很低,只有21%的人在12个月后还活着. 幸存者经常经历显著的功能障碍和受损的幸福感,突出需要专门的后ICU护理.
科学领域:
- 关键护理医学 关键护理医学
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 老年病的医生 老年病的医生
背景情况:
- 患有血液性恶性瘤 (HM) 的患者经常需要因严重疾病而入住重症监护室 (ICU).
- 这种易受伤害的人群在ICU出院后的长期生存和功能结果尚未确立.
研究的目的:
- 描述ICU入院后HM患者的12个月生存期和功能结果.
- 在这个队列中确定与12个月生存相关的因素.
主要方法:
- 从2018年到2020年,在加拿大七个ICU中进行了前性观察性研究.
- 招募了414名HM患者,幸存者在ICU出院后被跟踪了12个月.
- 评估了12个月的生存期,功能状态 (使用FIM和SF-36),以及脆弱性 (使用CFS).
主要成果:
- 整体12个月生存率为21% (在ICU幸存者中为43%).
- 在接受ICU治疗的22%患者中存在中度至重度的脆弱性,在幸存者中随着时间的推移而减少.
- 与人口规范相比,幸存者报告了显著的功能残疾和身体,社会和心理健康受损.
结论:
- 只有21%的重症HM患者在ICU出院后的12个月内存活下来.
- 存活率因血液学诊断和脆弱状态而异.
- 经历HM幸存者实质性的功能限制和生活质量下降,需要有针对性的支持性护理策略.
相关概念视频
Bone Marrow Sampling and Transplants
330
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
330
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Stem Cell Therapy for Tissue Regeneration
4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K


